A New ADC and The TULIP Trial
Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.
Luciano Costa, MD, PhD, Discusses Final Results of the MASTER Trial of Daratumumab Plus KRd in Multiple Myeloma
Luciano Costa, MD, PhD, spoke about the primary end point analysis for the MASTER trial examining daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma.
Key Takeaways and Impact on Maintenance Therapy Use in Clinical Practice
Drs. Brown and Gupta discuss key takeaways from the study and the impact these data are likely to have on clinical practice.
Sattva S. Neelapu, MD, Discusses Interesting Abstracts at 2021 ASH
Sattva S. Neelapu, MD, spoke about which abstracts he was most excited to see presented at the upcoming American Society of Hematology Annual Meeting.
Patient Case 2: A 53-Year-Old Woman With RCC
Dr Choueiri presents the second patient case to the panel: a 53-year-old woman with renal cell carcinoma that underwent a nephrectomy.
Managing Quality of Life in Patients With RCC
Dr Orenstein details how he manages quality of life for patients with advanced renal cell carcinoma.
Unmet Needs in nmCRPC
Aaron Berger, MD, shares unmet needs and challenges in managing patients with nmCRPC.
Quality of Life Data and Patient Preference in nmCRPC
Dr Aaron Berger comments on quality of life data and the role of patient preference in nmCRPC.
Comorbidities, Adherence and Dose Alterations in nmCRPC
A prostate cancer expert discusses comorbidities and dose alterations with next-generation androgen receptor inhibitors in nmCRPC.
A Review of the Data from the HER2CLIMB-04 and TUXEDO-1 Trials
Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.
Clinical Utility of the Data from ESMO 2021 in HER2+ Breast Cancer
The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.
Thomas G. Martin, MD, Discusses Updated Results of CARTITUDE-1 at ASH 2021
Thomas G. Martin, MD, spoke about the updated results of the CARTITUDE-1 study examining ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
Sattva S. Neelapu, MD, Discusses the Results of the ZUMA-5 Trial With Axi-Cel in R/R iNHL
Sattva S. Neelapu, MD, spoke about the ZUMA-5 trial and the long-term follow-up results seen with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Jennifer A. Woyach, MD, Discusses Previous Results of the AO41202 Trial Examining Ibrutinib Regimens in CLL
Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.
Luciano Costa, MD, PhD, Forecasts Exciting Abstracts at ASH 2021
Luciano Costa, MD, PhD, spoke about which abstracts he wants to see most at ASH 2021.
Thomas G. Martin, MD, on Results of CARTITUDE-1 and Other Data for Cilta-Cel at ASH 2021
Thomas G. Martin, MD, spoke about the previously reported results of the CARTITUDE-1 study in patients with relapsed or refractory myeloma ahead of the 2021 ASH Annual Meeting.
Thomas G. Martin, MD, Discusses Which Abstracts on BCMA Targeted Therapies He’s Excited to See at ASH 2021
Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.
Jennifer A. Woyach, MD, Discusses Exciting Abstracts at ASH 2021
Jennifer A. Woyach, MD, spoke about which abstracts she’s most excited to see presented at the 2021 American Society of Hematology Annual Meeting.
Metastatic Urothelial Carcinoma: Optimizing Frontline Maintenance Therapy
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
Selecting Frontline Therapy for Metastatic Urothelial Carcinoma
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
